DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Purchases 40,253 Shares

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg purchased 40,253 shares of DiaMedica Therapeutics stock in a transaction dated Monday, November 24th. The stock was bought at an average price of $7.89 per share, for a total transaction of $317,596.17. Following the completion of the transaction, the insider directly owned 8,752,643 shares in the company, valued at $69,058,353.27. The trade was a 0.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg acquired 73,099 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $8.57 per share, with a total value of $626,458.43.
• On Friday, November 21st, Jan Stahlberg bought 208,872 shares of DiaMedica Therapeutics stock. The shares were bought at an average price of $7.41 per share, for a total transaction of $1,547,741.52.
• On Thursday, November 20th, Jan Stahlberg bought 128,426 shares of DiaMedica Therapeutics stock. The shares were bought at an average price of $7.41 per share, with a total value of $951,636.66.
• On Wednesday, November 19th, Jan Stahlberg purchased 240,352 shares of DiaMedica Therapeutics stock. The stock was bought at an average cost of $7.21 per share, with a total value of $1,732,937.92.
• On Tuesday, November 18th, Jan Stahlberg acquired 182,882 shares of DiaMedica Therapeutics stock. The shares were purchased at an average price of $6.75 per share, with a total value of $1,234,453.50.
• On Monday, November 17th, Jan Stahlberg bought 187,393 shares of DiaMedica Therapeutics stock. The stock was purchased at an average cost of $6.52 per share, with a total value of $1,221,802.36.

DiaMedica Therapeutics Price Performance

DMAC traded down $0.02 during mid-day trading on Monday, hitting $8.76. The stock had a trading volume of 374,509 shares, compared to its average volume of 251,874. The stock’s fifty day simple moving average is $7.11 and its 200-day simple moving average is $5.70. The firm has a market capitalization of $456.22 million, a price-to-earnings ratio of -12.34 and a beta of 1.31. DiaMedica Therapeutics, Inc. has a 1-year low of $3.19 and a 1-year high of $9.23.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, research analysts expect that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DMAC has been the topic of a number of research analyst reports. Cowen initiated coverage on DiaMedica Therapeutics in a research report on Thursday, October 30th. They set a “buy” rating on the stock. Wall Street Zen downgraded shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. TD Cowen initiated coverage on shares of DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a “buy” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. acquired a new stake in DiaMedica Therapeutics in the 3rd quarter valued at $27,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of DiaMedica Therapeutics in the second quarter valued at about $29,000. Bank of America Corp DE raised its holdings in DiaMedica Therapeutics by 3,710.3% during the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after acquiring an additional 8,274 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in DiaMedica Therapeutics during the second quarter valued at approximately $49,000. Finally, Invesco Ltd. bought a new position in DiaMedica Therapeutics in the second quarter valued at approximately $54,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.